Organigram Global Inc. (TSE: OGI, NASDAQ: OGI) received a Nasdaq bid‑price deficiency notice on November 11 after its closing price stayed below $1 for 30 consecutive business days, giving the company until May 10, 2027 to regain compliance while its shares continue trading.
The notice references Nasdaq Listing Rule 5450(a)(1), and Organigram confirmed it does not affect its Toronto Stock Exchange listing or compliance status there.
Organigram operates as a Canadian cannabis cultivator and processor with manufacturing sites across several provinces and a medical cannabis business in Germany.
Shares closed at US$0.83 at 4:00 p.m. EST on November 13, according to Google Finance, preceding the public release of the notice.
Compliance Requires Consecutive Qualifying Bids
Organigram has 180 calendar days under Rule 5810(c)(3)(A) to bring its closing bid to at least $1 for a minimum of 10 consecutive business days, a threshold Nasdaq may extend at its discretion.
An isolated price spike does not satisfy the consecutive requirement, so the company must maintain qualifying closes throughout the period while its Nasdaq Global Select listing remains active.
“The Notification has no immediate effect on the listing or trading of the Company’s common shares on the Nasdaq Global Select Market,” Organigram stated in its release.
Acquisition and Competing Offers
The notice arrives as Organigram pursues the acquisition of Aurora Cannabis Inc. (TSE: ACB, NASDAQ: ACB), a deal valued at roughly C$561 million on a fully diluted basis, with shareholders able to select cash, Organigram shares, or a blend, subject to proration.
The share‑only election offers 5.8626 Organigram shares per Aurora share, while the cash‑only option is C$7.80 per share.
Competitor Curaleaf Holdings, Inc. (TSE: CURA, OTCMKTS: CURLF) announced on November 10 that it has secured required competition‑law clearances in Germany and Canada, with its offer set to expire December 4 unless withdrawn or amended.
Organigram’s compliance deadline is May 10, 2027; meeting the initial price requirement will determine whether it avoids further delisting proceedings, which could follow if it fails to qualify for an additional 180‑day period that would require a transfer to the Nasdaq Capital Market.
Statistics Canada reported preliminary, seasonally adjusted cannabis retail sales of C$492 million in August 2026, down 0.3 % from July and up 4.4 % year‑over‑year, providing a sector benchmark for domestic demand.
Meanwhile, MediPharm Labs Corp. (TSE: LABS, FRA: MLZ, OTCMKTS: MEDIF) posted quarterly revenue of C$11.8 million on November 12, an 18 % increase from the prior quarter driven by international medical sales.
